All In MedTech

FDA Clearance Tracker · P090013-S085

REVO MRI IPG

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 24, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 24, 2013

Approved

Time to decision

87 days

Received Feb 26, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P090013-S085
Device name
REVO MRI IPG
Applicant location
Mounds View, MN
Received
Feb 26, 2013
Decided
May 24, 2013
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P090013

Device type

Device class
Class III

Every decision under product code LWP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MYCARELINK PATIENT MONITOR MODELS 24950, 24951, READER MODEL 24955, AND ACCESSORIES, WHICH SUPPORT THE DEVICES.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.